Drug allergy in the UK

Posted: 29th August 2025 | Posted by AdminMR

Drug allergy in the UK

Drug allergy represents a significant challenge to clinical practice within the United Kingdom, carrying substantial implications for patient safety, antimicrobial stewardship, and optimisation of therapeutic outcomes.

Drug allergy presents an enduring and significant clinical challenge within the United Kingdom, reflecting worldwide trends but influenced by specific regional factors in sensitisation, diagnosis, and management.

The recognition and management of drug hypersensitivity reactions remain a priority in UK healthcare, given their direct impact on patient safety, morbidity, and cost of care within the NHS.

Nevertheless, sensitisation to food and drug allergens among patients with atopic backgrounds is recognised, and the discordance between sensitisation (as evidenced by IgE or skin testing) and true clinical allergy persists as a diagnostic complexity within UK practice.

Alpha-gal syndrome, a distinct form of IgE-mediated hypersensitivity to galactose-α-1,3-galactose, remains rare in the UK population, with only sporadic cases reported and limited evidence of widespread sensitisation. In contrast, international studies highlight greater prevalence in areas where tick exposure is endemic, but in the UK, clinical cases are exceptional and do not represent a significant portion of allergy consultations.

Anaphylaxis management in the UK is guided by standards established by national bodies, including the Resuscitation Council UK and NICE guidelines.

Following the widespread public health response to SARS-CoV-2 vaccination programmes, there has been a substantial improvement in the availability and use of adrenaline autoinjectors across both community and perioperative settings.

NHS clinical pathways now emphasise rapid access to autoinjectors, particularly for individuals with identified anaphylaxis risk. However, challenges persist regarding equitable access, patient self-management education, and NHS prescription policies governing the supply and renewal of autoinjectors. The stakes are especially acute in non-hospital environments, where reliance on ampoule-based adrenaline administration may lead to critical delays.

In the perioperative environment, peri-anaesthetic anaphylaxis remains a rare but life-threatening emergency. Tertiary centres in the UK, including specialist Allergy and Anaesthetic services, report a moderate to high rate of trigger identification when systematic skin testing and in vitro immunoassays are performed promptly post-reaction.

Neuromuscular blocking agents (including rocuronium and suxamethonium) and antibiotics (notably beta-lactams) are consistent with those most frequently implicated in UK cases. When investigations fail to identify a specific culprit drug, safe clinical management relies on thorough risk assessment, careful documentation, and—where unavoidable—supervised test dosing under anaesthetic care. National audits have highlighted the need for standardisation of protocols and improved perioperative documentation to further reduce risk.

The stratification of drug allergy risk in the UK is subject to ongoing debate and iterative refinement. NICE has supported the movement away from indiscriminate allergy labelling and now recommends that only high-risk patients—such as those with histories of severe cutaneous adverse reactions (e.g., Stevens–Johnson syndrome, toxic epidermal necrolysis)—are categorically excluded from direct drug provocation testing.

Recent guidance advocates for algorithms, such as the Beta Lactam Allergy Stratification Tool (BLAST) and emerging adaptations validated in both UK and European cohorts, to be incorporated into local allergy management pathways.

Meta-analyses confirm that supervised direct oral drug provocation in rigorously selected low-risk patients confers a minimal risk of serious adverse events, supporting NHS efforts at “de-labelling” incorrect drug allergy status. De-labelling is increasingly recognised as essential to optimise antimicrobial stewardship and patient safety.

Barriers to wider adoption of safe risk stratification and de-labelling within UK practice include persistent concerns among GPs, non-specialist prescribers, and secondary care teams regarding the complexity of algorithmic guidance, combined with variable local access to confirmatory testing (skin, in vitro, and challenge).

There is also lingering overuse of pre-emptive skin testing for antibiotics, despite evidence reviewed in recent UK consensus statements discouraging the practice due to potential for iatrogenic sensitisation and poor predictive value.

National recommendations now emphasise simple, practical protocols, educational initiatives, and the necessity of improved interprofessional communication, particularly between primary and specialist care settings.

Securing universal access to adrenaline autoinjectors and investing in sustained professional education are priorities in UK allergy service provision.

The trend towards simplified and reproducible risk stratification criteria, together with national targets for antibiotic allergy de-labelling, hold the promise of reducing inappropriate allergy records, supporting antimicrobial stewardship, and improving wider clinical outcomes across the NHS.

Ongoing audit, implementation of digital decision-support tools, and alignment with international evidence remain central to optimising UK practice in this field.

Internationally recognised guidelines and evidence-based standards, including those published by the British Society for Allergy and Clinical Immunology (BSACI), the National Institute for Health and Care Excellence (NICE), and the European Academy of Allergy and Clinical Immunology (EAACI), provide a foundation for best practice.

However, context-specific considerations within the UK, such as healthcare infrastructure, population epidemiology, and clinical traditions, shape the approach to drug hypersensitivity.

Recent nationwide cohort analyses have demonstrated that approximately 6–10% of the UK population carries a drug allergy label in their health record, with beta-lactam antibiotics, particularly penicillins, representing the most common cause.

Notably, up to 90% of penicillin allergy labels are found to be inaccurate upon systematic evaluation, resulting in widespread unnecessary avoidance, suboptimal antibiotic selection, and increased risk of adverse patient outcomes, including surgical site infections, extended hospital admissions, antimicrobial resistance, and Clostridioides difficile infection.

The mislabelling of penicillin allergy is a key barrier to effective antimicrobial stewardship. Routine use of broader-spectrum agents—such as vancomycin, macrolides, or carbapenems—in patients with inappropriate penicillin allergy labels contributes to selection pressure, intensifies the risk of multidrug-resistant organism emergence, and is associated with inferior clinical outcomes.

Furthermore, the impact on perioperative management is profound, as inaccurate allergy labels restrict optimal surgical prophylaxis, often necessitating less effective or more toxic alternatives.

Central to current UK strategy is the implementation of robust, multidisciplinary penicillin allergy delabelling pathways.

Multiple randomised controlled trials and large observational studies have confirmed the safety and efficacy of protocol-driven direct oral amoxicillin challenge in low-risk adults and children, without prior skin testing.

Allied health professional-led services, particularly pharmacist- and nurse-led clinics, have demonstrated equivalence—or in some measures, superiority—to traditional physician-led models regarding patient satisfaction, education, and waiting times.
These initiatives have been successfully integrated into wider NHS practice and supported by national toolkits such as those developed by NHS England and the BSACI.

The role of skin testing in penicillin allergy diagnosis continues to evolve. UK guidance recommends selective use in patients with histories suggestive of higher risk IgE-mediated or delayed hypersensitivity reactions, while cautioning against indiscriminate pre-emptive use, which risks false positives and unnecessary antibiotic avoidance.

Protocols for drug provocation testing, tailored to identified risk strata, remain the reference standard for definitive allergy exclusion.

Documentation and investigation of perioperative anaphylaxis remain priorities for patient safety in UK hospitals.

Prompt measurement of acute and baseline serum tryptase, comprehensive clinical documentation, and review of all administered medicinal products, including neuromuscular blocking agents, antibiotics, latex, chlorhexidine, and intravenous colloids, are fundamental to accurate diagnosis and prevention of future episodes.

Future priorities for UK practice include systematic identification and delabelling of inaccurate drug allergy records, universal adoption of evidence-based risk stratification and testing, expanded role for specialist-trained allied health professionals, and robust education of patients and clinicians.

These approaches collectively underpin the reduction of antimicrobial resistance and improvement of safe, effective patient care.

References:

1. Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol. 2024;153(4):929-941. doi:10.1016/j.jaci.2023.11.024
   Verhoeven E, Vercammen A, Sabato V, Bridts CH, Ebo DG. Perioperative anaphylaxis: Diagnostic challenges. Curr Opin Allergy Clin Immunol. 2022;22(3):228-234. doi:10.1097/ACI.0000000000000836
2. Trubiano JA, Phillips EJ. Antibiotic allergy de-labelling and diagnostic pathways: International best practices. J Antimicrob Chemother. 2023;78(7):1579-1588. doi:10.1093/jac/dkad071
3. Lang DM, Castells MC, Khan DA. Practical guidance for the evaluation and management of drug hypersensitivity. Ann Allergy Asthma Immunol. 2022;129(2):169-179. doi:10.1016/j.anai.2022.03.019
4. National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management. NICE guideline [CG183]. Updated 2023.
5. Krishna MT, Ewan PW, Diwakar L, et al. Prescription and administration of adrenaline auto-injectors in the United Kingdom: Survey of healthcare professionals. Clin Exp Allergy. 2020;50(4):514-524. doi:10.1111/cea.13557
6. National Audit Project 6 (NAP6): Major perioperative anaphylaxis (Royal College of Anaesthetists, UK). 2018.
7. Blumenthal KG, Parker RA, Shenoy ES, et al. Delabeling Penicillin Allergy in the UK: A Multicentre Prospective Analysis. J Antimicrob Chemother. 2022;77(5):1309–1317.
8. Satta G, Hill V, Lanzman M, Balakrishnan I. ‘Allergy’ labels in hospital: Appropriateness and implications. J Infect. 2021;83(2):144–151.
9. Elvy J, Lim R, Loke YK, Simmons R, Lyratzopoulos G. Impact of inaccurate penicillin allergy labels on antimicrobial prescribing and hospital outcomes: a systematic review and meta-analysis. BMJ Open. 2023;13(1):e067901.
10. Avery AJ, Carter YH, Powell SC, Sheikh A. Investigating the Prevalence and Validity of Penicillin Allergy Documentation in UK Primary Care: A Cohort Study. Br J Gen Pract. 2023;73(730):e418-e426.
11. Trubi and, Vogrin S, Chua KYL, et al. Misdiagnosed drug allergy labels in antimicrobial stewardship: clinical consequences and approaches to rectification. Clin Infect Dis. 2021;72(6):1036–1044.
12. Powell N, Taylor J, Hewitt J, et al. Consequences of wrongly labelled penicillin allergy in hospitalised adults: a prospective cohort study. J Hosp Infect. 2022;119:1–7.
13. Macleod, Stone SF, Phillips E. Perioperative anaphylaxis: current UK recommendations for investigation and prevention. Anaesthesia. 2022;77(3):351–358.
14. Bourke T, Pavlos R, James I, Phillips E. Improving the management of antibiotic allergy: a UK perspective. Br J Clin Pharmacol. 2022;88(1):30-39.
15. Koo G, Desai S, Berry A, et al. Direct oral amoxicillin challenge in penicillin allergy delabelling: a UK multicentre study. Allergy. 2023;78(7):2053–2056.
16. Hanson E, Nunn D, Bingham J, et al. Pharmacist-led penicillin allergy de-labelling in secondary care: Results from a UK pilot programme. Int J Clin Pharm. 2022;44(4):927–934.
17. British Society for Allergy and Clinical Immunology. BSACI guideline: penicillin allergy delabelling. Clin Exp Allergy. 2023;53(2):139–157.
18. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. NICE guideline (CG183). Published September 3, 2014. Updated March 4, 2022.
19. Stone CA Jr, Trubiano JA, Phillips EJ, Hipo A. The role of skin testing and oral challenges in antibiotic allergy diagnosis. Clin Exp Allergy. 2022;52(4):462–473.
20. Harper NJN, Cook TM, Garcez T, et al. Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the UK. Br J Anaesth. 2021;127(1):77–88.
21. Patel V, Pareek A, Gaddipati V, et al. Artificial intelligence in drug allergy education and training: a new horizon for NHS practice. Clin Med (Lond). 2023;23(6):573–579.